SINGAPORE--(Marketwired - Apr 10, 2013) -  Veredus

New Post Public Reply Private Reply Replies (0) Message Board
testuser
SINGAPORE--(Marketwired - Apr 10, 2013) -  Veredus Laboratories today announced that the current version of VereFlu detects the current subtype of H7N9 (Avian Flu) that is responsible for the Flu outbreak in China. H7N9 is the latest mutation to cause concern and increased surveillance in the region. Launched in 2008 and built on the STMicroelectronics (NYSE: STM) lab-on-chip platform, VereFlu run on Veredus' VerePLEX™ biosystem is the market's first test to integrate two powerful molecular biological applications, Polymerase Chain Reaction (PCR) and a microarray, onto a Lab-on-Chip platform. VereFlu is a portable lab-on-chip application for rapid detection of all major influenza types at the point of need. Unlike existing diagnostic methods, VereFlu is a breakthrough molecular diagnostic test that can detect infection with high accuracy and sensitivity, within two hours, providing genetic information on the infection that traditionally could take days to weeks to learn. With its high level of automation, users outside the traditional lab environment can easily perform the tests at the point of need. In addition to the current H7N9 Avian Flu, VereFlu is proven to identify and differentiate human subtypes of Influenza A (H1, H3, H5, H7, H9) and B viruses, including the Avian Flu subtype H5N1, and the 2009 pandemic H1N1/2009, all in a single test. "After learning of the outbreak in China, we have confirmed in-silico[1] that our current VereFlu influenza panel is able to detect the subtype of H7N9 responsible for this outbreak in addition to other human Flu A and B infections," said Rosemary Tan, chief executive officer of Veredus. "This confirms our vision when we designed the panel for the need to have a multiplexed molecular test to detect not only the typical seasonal influenza subtypes but also novel emerging subtypes, including the current H7N9 subtype, capable of making the jump from animals to humans. Our customers can be assured that with VereFlu they are able to detect H7N9 and we are able to deliver immediately a fast, reliable surveillance system that can be deployed to help monitor the current situation." About Veredus Laboratories Pte Ltd Veredus Laboratories Pte Ltd was founded in 2003 and launched its first products in 2005. Veredus is a Singapore-based majority-owned subsidiary of STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications. Veredus specializes in the development, manufacture, and marketing of innovative multiplexed molecular solutions in the clinical, specialty, and custom testing markets based on STMicroelectronics' proprietary Lab-on-Chip platform. The Lab-on-Chip platform, marketed as the VerePLEX™ biosystem, combines Micro-Electro-Mechanical-Systems (MEMS) with micro-fluidics to integrate multiplexed DNA amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials. About STMicroelectronics ST is a global leader in the semiconductor market serving customers across the spectrum of sense and power and automotive products and embedded processing solutions. From energy management and savings to trust and data security, from healthcare and wellness to smart consumer devices, in the home, car and office, at work and at play, ST is found everywhere microelectronics make a positive and innovative contribution to people's life. By getting more from technology to get more from life, ST stands for life.augmented. In 2012, the Company's net revenues were $8.49 billion. Further information on ST can be found at www.st.com. VereFlu and VerePLEX are trademarks of Veredus Laboratories. [1] in simulations based on known DNA sequences of H7N9 VereFlu Lab on Chip http://hugin.info/152740/R/1691826/555686.pdf VereFlu Lab on Chip_IMAGE http://hugin.info/152740/R/1691826/555688.jpg For further information, please contact:Boey Taik BoonCorporate External Communications STMicroelectronics Asia-Pacific Tel: +65 6427 7765 Email: taik-boon.boey@st.comHazelle LamDirector, Sales and Marketing Veredus Laboratories Pte Ltd Mobile: +65 9431 3790 Email: hazelle.lam@vereduslabs.comTony BarbuzziBusiness Development Manager STMicroelectronics, SRL Mobile : +393400872836 Email : tony.barbuzzi@st.com

View More
Investors-Hangout-Stock-Message-Boards-thumbnail-2015.png

test123 kjk
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

iCapital Enhances Portfolio Solutions For Global Investors

Updated Category News Views 267

iCapital Enhances Portfolio Construction Tools for Investors iCapital, a leading global fintech platform, has introduced significant enhancements to its innovative portfolio construction tool, iCapital Architect. This advanced platform is designed to simplify the integration of alternative investments into traditional portfolio strategies. Financial advisors gain access...

Continue Reading
Market Adaptability: S&P 500 Faces Correction Ahead

Updated Category News Views 210

Understanding Recent Market Movements The market experienced a turbulent session recently, sending investors into a state of caution. This volatility was significantly influenced by renewed discussions around tariffs impacting trade relationships, particularly involving technology and manufacturing sectors. The Impact of Tariffs on the Market Former President Trump's...

Continue Reading
Performance Systems Integration Merges with Summit Fire & Security

Updated Category News Views 177

Performance Systems Integration Merger with Summit Fire & Security Performance Systems Integration (PSI), recognized as the leading fire and life safety solutions provider in the Pacific Northwest, has completed a merger with Summit Fire & Security LLC, which is a subsidiary of SFP Holding, Inc. This merger marks a significant collaboration that aims to enhance the safety...

Continue Reading
Candel Therapeutics Shares Optimistic Findings on CAN-3110

Updated Category News Views 159

Revealing Interim Results from Candel Therapeutics NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company dedicated to advancing biological immunotherapies to combat cancer, has announced noteworthy interim data stemming from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) targeting recurrent glioblastoma. This...

Continue Reading
Supernus Pharmaceuticals Reaches New Heights with Strong Growth

Updated Category News Views 83

Supernus Pharmaceuticals Hits Record Stock Levels Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has achieved a remarkable milestone, as its stock recently surged to a 52-week high of $35.45. This significant increase showcases the company’s strong financial performance and growth prospects, creating a wave of optimism among investors. The stock has risen an impressive...

Continue Reading